A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemic

- Lal, Anoushka P., Foong, Yi Chao, Roos, Izanne, Lechner-Scott, Jeannette, John, Nevin, Soysal, Aysun, D’Amico, Emanuele, Gouider, Riadh, Mrabet, Saloua, Gross-Paju, Katrin, Cárdenas‑Robledo, Simón, Moghadasi, Abdorreza Naser, Sanfilippo, Paul G., Sa, Maria Jose, Gray, Orla, Oh, Jiwon, Reddel, Stephen, Ramanathan, Sudarshini, Al-Harbi, Talal, Altintas, Ayse, Hardy, Todd A., Ozakbas, Serkan, Alroughani, Raed, Spelman, Tim, Kermode, Allan G., Surcinelli, Andrea, Laureys, Guy, Eichau, Sara, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Hodgkinson, Suzanne, Ramo-Tello, Cristina, Maimone, Davide, Rath, Louise, McCombe, Pamela, Spitaleri, Daniele, Sanchez-Menoyo, Jose Luis, Yetkin, Mehmet Fatih, Baghbanian, Seyed Mohammad, Karabudak, Rana, Al-Asmi, Abdullah, Jakob, Gregor Brecl, Khoury, Samia J., Etemadifar, Masoud, Levitz, David, van Pesch, Vincent, Buzzard, Katherine, Taylor, Bruce, Butzkueven, Helmut, Van der Walt, Anneke, Fabis-Pedrini, Marzena, Foschi, Matteo, Habek, Mario, Kalincik, Tomas

Comparative effectiveness of dimethyl fumarate versus non-specific immunosuppressants: Real-world evidence from MSBase

- Spelman, Tim, Eichau, Sara, Grammond, Pierre, Lechner-Scott, Jeanette, Gray, Orla, Amato, Maria Pia, Laureys, Guy, Shaygannejad, Vahid, Hyde, Robert, Wang, Haijue, Bozin, Ivan, Belviso, Nicholas, Alroughani, Raed, Quan, Chao, Zeng, Feng, van der Walt, Anneke, Butzkueven, Helmut, MSBase Study Group,, Ozakbas, Serkan, Khoury, Samia J, Patti, Francesco, Havrdova, Eva Kubala, Boz, Cavit, Terzi, Murat, Kuhle, Jens

Disease Activity in Pregnant and Postpartum Women With Multiple Sclerosis Receiving Ocrelizumab or Other Disease-Modifying Therapies

- Yeh, Wei Z., Van Der Walt, Anneke, Ozakbas, Serkan, Buzzard, Katherine, Habek, Mario, John, Nevin A., Prat, Alexandre, Girard, Marc, Duquette, Pierre, Baghbanian, Seyed Mohammad, Hodgkinson, Suzanne, Van Pesch, Vincent, Skibina, Olga G., Laureys, Guy, Willekens, B, Prevost, J, Foschi, M, De Gans, K, Horakova, D, Havrdova, EK, Karabudak, R, Patti, F, Mccombe, PA, Kalincik, Tomas, Maimone, D, Altintas, A, Ampapa, R, Spitaleri, D, Gerlach, OHH, Sa, MJ, Hughes, S, Gouider, R, Mrabet, S, Macdonell, RA, Alroughani, Raed, Turkoglu, R, Cartechini, E, Al-Asmi, A, Soysal, A, Oh, J, Muros-Le Rouzic, E, Guye, S, Pasquarelli, N, Butzkueven, H, Jokubaitis, VG, Kermode, Allan G., MSBase Study Group,, Fabis-Pedrini, Marzena J., Carroll, William M., Lechner-Scott, Jeannette, Boz, Cavit

Examining the environmental risk factors of progressive-onset and relapsing-onset multiple sclerosis: recruitment challenges, potential bias, and statistical strategies

- Li, Ying, Saul, Alice, Eichau, Sara, Onofrj, Marco, Ozakbas, Serkan, Horakova, Dana, Havrdova, Eva Kubala, Grand'Maison, Francois, Alroughani, Raed, Gerlach, Oliver, Amato, Maria Pia, Altintas, Ayse, Taylor, Bruce, Girard, M, Duquette, P, Blanco, Y, Ramo-Tello, C, Laureys, G, Kalincik, T, Khoury, SJ, Shaygannejad, V, Etemadifar, M, Singhal, B, Ponsonby, Anne-Louise, Mrabet, S, Foschi, M, Habek, M, John, N, Hughes, S, McCombe, P, Ampapa, R, van der Walt, A, Butzkueven, H, de Gans, K, Simpson-Yap, Steve, McGuigan, C, Oreja-Guevara, C, Sa, MJ, Petersen, T, Al-Harbi, T, Sempere, AP, Van Wijmeersch, B, Grigoriadis, N, Prevost, J, Gray, O, Blizzard, Leigh, Castillo-Trivino, T, Macdonell, R, Lugaresi, A, Sajedi, SA, van der Mei, I, Broadley, Simon, Lechner-Scott, Jeannette, Karabudak, Rana, Patti, Francesco

A plain language summary on the effectiveness of cladribine tablets compared with other oral treatments for multiple sclerosis: results from the MSBase registry

- Spelman, Tim, Ozakbas, Serkan, Soysal, Aysun, Kuhle, Jens, Sanchez-Menoyo, Jose Luis, Morgado, Yolanda Blanco, Spitaleri, Daniele L. A., Pesch, Vincent Van, Horakova, Dana, Ampapa, Radek, Patti, Francesco, Macdonell, Richard, Alroughani, Raed, Al-Asmi, Abdullah, Gerlach, O, Oh, J, Altintas, A, Tundia, N, Wong, SL, Butzkueven, H, MSBase Study Group,, Terzi, Murat, Hodgkinson, Suzanne, Laureys, Guy, Kalincik, Tomas, Der Walt, Anneke Van, Yamout, Bassem, Lechner-Scott, Jeannette

Comparative effectiveness in multiple sclerosis: A methodological comparison

- Roos, Izanne, Diouf, Ibrahima, Onofrj, Marco, Lugaresi, Alessandra, Alroughani, Raed, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Terzi, Murat, Boz, Cavit, Grand'Maison, Francois, Sola, Patrizia, Sharmin, Sifat, Ferraro, Diana, Grammond, P, Turkoglu, R, Buzzard, K, Skibina, O, Yamou, B, Altintas, A, Gerlach, O, van Pesch, V, Blanco, Y, Horakova, Dana, Maimone, D, Lechner-Scott, Jeannette, Bergamaschi, R, Karabudak, R, McGuigan, C, Cartechini, E, Barnett, M, Hughes, S, Sa, MJ, Solaro, C, Havrdova, Eva Kubala, Ramo-Tello, C, Hodgkinson, S, Spitaleri, D, Soysal, A, Petersen, T, Granella, F, de Gans, K, McCombe, P, Ampapa, R, Van Wijmeersch, B, Patti, Francesco, van der Walt, A, Butzkueven, H, Prevost, J, Sanchez-Menoyo, JL, Laureys, G, Gouider, R, Castillo-Triviño, T, Gray, O, Aguera-Morales, E, Al-Asmi, A, Shaygannejad, Vahid, Shaw, C, Deri, N, Al-Harbi, T, Fragoso, Y, Csepany, T, Sempere, AP, Trevino-Frenk, I, Schepel, J, Moore, F, Malpas, C, Ozakbas, Serkan, Kalincik, T, Izquierdo, Guillermo, Eichau, Sara

Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry

- Spelman, Tim, Ozakbas, Serkan, Soysal, Aysun, Kuhle, Jens, Sanchez-Menoyo, Jose Luis, Blanco Morgado, Yolanda, Spitaleri, Daniele L. A., van Pesch, Vincent, Horakova, Dana, Ampapa, Radek, Patti, Francesco, Macdonell, Richard, Alroughani, Raed, Al-Asmi, A, Gerlach, O, Oh, J, Altintas, A, Tundia, N, Wong, SL, Butzkueven, H, Terzi, Murat, Hodgkinson, Suzanne, Laureys, Guy, Kalincik, Tomas, Van Der Walt, Anneke, Yamout, Bassem, Lechner-Scott, Jeannette

Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation

- Zhu, Chao, Kalincik, Tomas, Patti, Francesco, Grand'Maison, Francois, Hodgkinson, Suzanne, Grammond, Pierre, Lechner-Scott, Jeannette, Butler, Ernest, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Macdonell, Richard A. L., Horakova, Dana, Weinstock-Guttman, B, Ozakbas, S, Slee, M, Sa, MJ, Van Pesch, V, Barnett, M, Van Wijmeersch, B, Gerlach, O, Prevost, J, Terzi, M, Zhou, Zhen, Boz, C, Laureys, G, Van Hijfte, L, Kermode, AG, Garber, J, Yamout, B, Khoury, SJ, Merlo, D, Monif, M, Jokubaitis, V, Buzzard, Katherine, van der Walt, A, Butzkueven, H, MSBase, SG, Skibina, Olga, Alroughani, Raed, Izquierdo, Guillermo, Eichau, Sara, Kuhle, Jens

Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis

- Daruwalla, Cyrus, Shaygannejad, Vahid, Eichau, Sara, Girard, Marc, Prat, Alexandre, Duquette, Pierre, Yamout, Bassem, Khoury, Samia J., Sajedi, Seyed Aidin, Turkoglu, Recai, Altintas, Ayse, Skibina, Olga, Ozakbas, Serkan, Buzzard, Katherine, Grammond, P, Karabudak, R, van der Walt, A, Butzkueven, H, Maimone, D, Lechner-Scott, Jeannette, Soysal, A, John, N, Prevost, J, Havrdova, Eva Kubala, Spitaleri, D, Ramo-Tello, C, Gerlach, O, Iuliano, G, Foschi, M, Ampapa, R, van Pesch, V, Barnett, M, Shalaby, N, D'hooghe, M, Horakova, Dana, Kuhle, J, Sa, MJ, Fabis-Pedrini, M, Kermode, A, Mrabet, S, Gouider, R, Hodgkinson, S, Laureys, G, Van Hijfte, L, Macdonell, R, Alroughani, Raed, Oreja-Guevara, C, Cristiano, E, McCombe, P, Sanchez-Menoyo, JL, Singhal, B, Blanco, Y, Hughes, S, Garber, J, Solaro, C, McGuigan, C, Boz, Cavit, Taylor, B, de Gans, K, Habek, M, Al-Asmi, A, Mihaela, S, Castillo Triviño, T, Al-Harbi, T, Rojas, JI, Gray, O, Khurana, D, Patti, Francesco, Van Wijmeersch, B, Grigoriadis, N, Inshasi, J, Oh, J, Aguera-Morales, E, Fragoso, Y, Moore, F, Shaw, C, Baghbanian, SM, Shuey, N, Onofrj, Marco, Willekens, B, Hardy, TA, Decoo, D, Sempere, AP, Field, D, Wynford-Thomas, R, Cunniffe, NG, Roos, I, Malpas, CB, Coles, AJ, Lugaresi, Alessandra, Kalincik, T, Brown, JWL

Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial

- Diouf, Ibrahima, Malpas, Charles B., Onofrj, Marco, Lugaresi, Alessandra, Alroughani, Raed, Prat, Alexandre, Duquette, Pierre, Terzi, Murat, Boz, Cavit, Grand'Maison, Francois, Sola, Patrizia, Ferraro, Diana, Sharmin, Sifat, Grammond, P, Yamout, B, Altintas, A, Gerlach, O, Lechner-Scott, Jeannette, Bergamaschi, R, Karabudak, R, Iuliano, G, McGuigan, C, Cartechini, E, Roos, Izanne, Hughes, S, Sa, MJ, Solaro, C, Kappos, L, Hodgkinson, S, Slee, M, Granella, F, de Gans, K, McCombe, PA, Ampapa, R, Horakova, Dana, van der Walt, A, Butzkueven, H, Sánchez-Menoyo, JL, Vucic, S, Laureys, G, Sidhom, Y, Gouider, R, Castillo-Trivino, T, Gray, O, Aguera-Morales, E, Kubala Havrdova, Eva, Al-Asmi, A, Shaw, C, Al-Harbi, TM, Csepany, T, Sempere, AP, Treviño Frenk, I, Stuart, EA, Kalincik, T, Patti, Francesco, Shaygannejad, Vahid, Ozakbas, Serkan, Eichau, Sara

Predictors of treatment switching in the Big Multiple Sclerosis Data Network

- Spelman, Tim, Magyari, Melinda, Hyde, Robert, Duquette, Pierre, Lechner-Scott, Jeannette, Sajedi, Seyed Aidin, Lalive, Patrice, Shaygannejad, Vahid, Ozakbas, Serkan, Eichau, Sara, Alroughani, Raed, Terzi, Murat, Butzkueven, Helmut, Girard, Marc, Kalincik, T, Grand'Maison, F, Skibina, O, Khoury, SJ, Yamout, B, Sa, MJ, Gerlach, O, Blanco, Y, Karabudak, R, Van Der Walt, Anneke, Oreja-Guevara, C, Altintas, A, Hughes, S, Mccombe, P, Ampapa, R, de Gans, K, Mcguigan, C, Soysal, A, Prevost, J, John, N, Vukusic, Sandra, Inshasi, J, Stawiarz, L, Manouchehrinia, A, Forsberg, L, Sellebjerg, F, Glaser, A, Pontieri, L, Joensen, H, Rasmussen, PV, Sejbaek, T, Trojano, Maria, Poulsen, MB, Christensen, JR, Kant, M, Stilund, M, Mathiesen, H, Hillert, J, Iaffaldano, Pietro, Horáková, Dana, Drahota, Jiří, Pellegrini, Fabio

Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis

- Roos, Izanne, Hughes, Stella, van der Walt, Anneke, Butzkueven, Helmut, Lechner-Scott, Jeannette, Kuhle, Jens, Terzi, Murat, Laureys, Guy, Van Hijfte, Liesbeth, John, Nevin, Grammond, Pierre, Grand'Maison, Francois, McDonnell, Gavin, Soysal, Aysun, Jensen, AV, Rasmussen, PV, Svendsen, KB, Barzinji, I, Nielsen, HH, Sejbæk, T, Prakash, S, Stilund, MLM, Weglewski, A, Malpas, Charles B., Issa, NM, Kant, M, Sellebjerg, F, Gray, O, Magyari, M, Kalincik, T, MSBase Study GroupDanish MS Registry Study Group,, Sharmin, Sifat, Boz, Cavit, Alroughani, Raed, Ozakbas, Serkan, Buzzard, Katherine, Skibina, Olga

Switching to natalizumab or fingolimod in multiple sclerosis: Comparative effectiveness and effect of pre-switch disease activity

- Spelman, Tim, Horakova, Dana, Csepany, Tunde, Boz, Cavit, Lechner-Scott, Jeannette, Granella, Franco, Grand'Maison, Francois, van der Walt, Anneke, Zhu, Chao, Butzkueven, Helmut, Ozakbas, Serkan, Alroughani, Raed, Onofrj, Marco, Kalincik, Tomas, Prat, Alexandre, Terzi, Murat, Grammond, Pierre, Patti, Francesco

The risk of secondary progressive multiple sclerosis is geographically determined but modifiable

- Sharmin, Sifat, Roos, Izanne, Izquierdo, Guillermo, Eichau, Sara, Boz, Cavit, Zakaria, Magd, Onofrj, Marco, Lugaresi, Alessandra, Weinstock-Guttman, Bianca, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Simpson-Yap, Steve, Lechner-Scott, Jeannette, Amato, MP, Karabudak, R, Grand'Maison, F, Khoury, SJ, Grammond, P, Lechner-Scott, J, Buzzard, K, Skibina, O, van der Walt, A, Malpes, Charles, Butzkueven, H, Turkoglu, R, Altintas, A, Maimone, D, Kermode, A, Shalaby, N, Pesch, VV, Butler, E, Sidhom, Y, Gouider, R, Sánchez, Marina M., Mrabet, S, Gerlach, O, Soysal, A, Barnett, M, Kuhle, J, Hughes, S, Sa, MJ, Hodgkinson, S, Oreja-Guevara, C, Ampapa, R, Ozakbas, Serkan, Petersen, T, Ramo-Tello, C, Spitaleri, D, McCombe, P, Taylor, B, Prevost, J, Foschi, M, Slee, M, McGuigan, C, Laureys, G, Horakova, Dana, Hijfte, LV, de Gans, K, Solaro, C, Oh, J, Macdonell, R, Aguera-Morales, E, Singhal, B, Gray, O, Garber, J, Wijmeersch, BV, Havrdova, Eva K., Simu, M, Castillo-Trivino, T, Sanchez-Menoyo, JL, Khurana, D, Al-Asmi, A, Al-Harbi, T, Deri, N, Fragoso, Y, Lalive, PH, Sinnige, LGF, Patti, Francesco, Shaw, C, Shuey, N, Csepany, T, Sempere, AP, Moore, F, Decoo, D, Willekens, B, Gobbi, C, Massey, J, Hardy, T, Alroughani, Raed, Parratt, J, Kalincik, T

Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis

- Diouf, Ibrahima, Malpas, Charles B., Eichau, Sara, Onofrj, Marco, Lugaresi, Alessandra, Alroughani, Raed, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Terzi, Murat, Boz, Cavit, Grand'Maison, Francois, Sharmin, Sifat, Lechner-Scott, Jeannette, Sola, P, Ferraro, D, Grammond, P, Turkoglu, R, Buzzard, K, Skibina, O, Yamout, B, Altintas, A, Gerlach, O, Roos, Izanne, van Pesch, V, Blanco, Y, Maimone, D, Lechner-Scott, J, Bergamaschi, R, Karabudak, R, Iuliano, G, McGuigan, C, Cartechini, E, Barnett, M, Horakova, Dana, Hughes, S, Sa, MJ, Solaro, C, Kappos, L, Ramo-Tello, C, Cristiano, E, Hodgkinson, S, Spitaleri, D, Soysal, A, Petersen, T, Havrdova, Eva Kubala, Slee, M, Butler, E, Granella, F, de Gans, K, McCombe, P, Ampapa, R, Van Wijmeersch, B, van der Walt, A, Butzkueven, H, Prevost, J, Patti, Francesco, Sinnige, LGF, Sanchez-Menoyo, JL, Vucic, S, Laureys, G, Van Hijfte, L, Khurana, D, Macdonell, R, Gouider, R, Castillo-Trivino, T, Gray, O, Shaygannejad, Vahid, Aguera-Morales, E, Al-Asmi, A, Shaw, C, Deri, N, Al-Harbi, T, Fragoso, Y, Csepany, T, Sempere, AP, Trevino-Frenk, I, Schepel, J, Ozakbas, Serkan, Moore, F, Kalincik, T, Izquierdo, Guillermo

Association of Latitude and Exposure to Ultraviolet B Radiation With Severity of Multiple Sclerosis: An International Registry Study

- Vitkova, Marianna, Diouf, Ibrahima, Onofrj, Marco, Lugaresi, Alessandra, Alroughani, Raed, Prat, Alexandre, Larochelle, Catherine, Girard, Marc, Duquette, Pierre, Terzi, Murat, Boz, Cavit, Grand'Maison, Francois, Malpas, Charles, Sola, Patrizia, Ferraro, D, Grammond, P, Butzkueven, H, Buzzard, K, Skibina, O, Yamout, BI, Karabudak, R, Gerlach, O, Lechner-Scott, Jeannette, Horakova, Dana, Maimone, D, Bergamaschi, R, Van Pesch, V, Iuliano, G, Cartechini, E, José Sà, M, Ampapa, R, Barnett, M, Hughes, SE, Ramo-Tello, CM, Kubala Havrdova, Eva, Hodgkinson, S, Spitaleri, DLA, Petersen, T, Butler, EG, Slee, M, McGuigan, C, McCombe, PA, Granella, F, Cristiano, E, Prevost, J, Patti, Francesco, Taylor, BV, Sãnchez-Menoyo, JL, Laureys, G, Van Hijfte, L, Vucic, S, Macdonell, RA, Gray, O, Olascoaga, J, Deri, N, Fragoso, YD, Ozakbas, Serkan, Shaw, C, Kalincik, T, MSBase Study Group,, Izquierdo, Guillermo, Eichau, Sara, Shaygannejad, Vahid

Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis

- Zhu, Chao, Zhou, Zhen, Roos, Izanne, Merlo, Daniel, Kalincik, Tomas, Ozakbas, Serkan, Skibina, Olga, Kuhle, Jens, Hodgkinson, Suzanne, Boz, Cavit, Alroughani, Raed, Lechner-Scott, Jeannette, Barnett, Michael, Izquierdo, Guillermo, Prat, Alexandre, Horakova, Dana, Havrdova, Eva Kubala, Macdonell, Richard, Patti, Francesco, Khoury, Samia Joseph

Confirmed disability progression as a marker of permanent disability in multiple sclerosis

- Sharmin, Sifat, Bovis, Francesca, Duquette, Pierre, Onofrj, Marco, Lugaresi, Alessandra, Grand'Maison, Francois, Grammond, Pierre, Sola, Patrizia, Ferraro, Diana, Terzi, Murat, Gerlach, Oliver, Alroughani, Raed, Malpas, Charles, Boz, C, Shaygannejad, V, van Pesch, V, Cartechini, E, Kappos, L, Lechner-Scott, Jeanette, Bergamaschi, R, Turkoglu, R, Solaro, C, Iuliano, G, Horakova, Dana, Granella, F, Van Wijmeersch, B, Spitaleri, D, Slee, M, McCombe, P, Prevost, J, Ampapa, R, Ozakbas, S, Sanchez-Menoyo, JL, Soysal, A, Havrdova, Eva Kubala, Vucic, S, Petersen, T, de Gans, K, Butler, E, Hodgkinson, S, Sidhom, Y, Gouider, R, Cristiano, E, Castillo-Trivino, T, Saladino, ML, Izquierdo, Guillermo, Barnett, M, Moore, F, Rozsa, C, Yamout, B, Skibina, O, van der Walt, A, Buzzard, K, Gray, O, Hughes, S, Sempere, AP, Eichau, Sara, Singhal, B, Fragoso, Y, Shaw, C, Kermode, A, Taylor, B, Simo, M, Shuey, N, Al-Harbi, T, Macdonell, R, Dominguez, JA, Trojano, Maria, Csepany, T, Sirbu, CA, Sormani, MP, Butzkueven, H, Kalincik, T, Prat, Alexandre, Girard, Marc

Multiple Sclerosis Relapses Following Cessation of Fingolimod

- Malpas, Charles B., Roos, Izanne, Havrdova, Eva Kubala, Izquierdo, Guillermo, Eichau, Sara, Hodgkinson, Suzanne, Grammond, Pierre, Lechner-Scott, Jeannette, Kalincik, Tomas, MSBase Study Group,, Sharmin, Sifat, Buzzard, Katherine, Skibina, Olga, Butzkueven, Helmut, Kappos, Ludwig, Patti, Francesco, Alroughani, Raed, Horakova, Dana

Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS

- Kalincik, Tomas, Kister, Ilya, Ozakbas, Serkan, Onofrj, Marco, Lugaresi, Alessandra, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Grammond, Pierre, Sola, Patrizia, Ferraro, Diana, Alroughani, Raed, Bacon, Tamar E., Terzi, Murat, Boz, C, Grand'Maison, F, Bergamaschi, R, Gerlach, O, Sa, MJ, Kappos, L, Cartechini, E, Lechner-Scott, Jeannette, van Pesch, V, Malpas, Charles B., Shaygannejad, V, Granella, F, Spitaleri, D, Iuliano, G, Maimone, D, Prevost, J, Soysal, A, Turkoglu, R, Ampapa, R, Butzkueven, H, Sharmin, Sifat, Cutter, G, for MSBase Study Group,, Horakova, Dana, Kubala-Havrdova, Eva, Patti, Francesco, Izquierdo, Guillermo, Eichau, Sara